Arrayit Corporation (OTCBB: ARYC) announced today that the company's majority owned subsidiary, Arrayit Diagnostics, Inc., will launch the most intensive marketing campaign in the company's thirteen-year history. The company is currently developing several diagnostic tests that will provide early detection for cancers, neurodegenerative diseases and other disease states. By conclusively identifying the genomic and proteomic biomarkers for specific diseases, these tests will enable early stage diagnosis, leading to life saving and cost saving treatments. Arrayit Diagnostics will promote the commercialization of these tests from its international headquarters in Houston, Texas.
Arrayit Diagnostics has named John Howell as its CEO and President. "Arrayit Diagnostics has the potential to globally renovate the health care sector, allowing the diagnostics community to rethink the way diseases are diagnosed and treated. Rather than reacting after symptoms have already appeared, our tests will allow early detection, enabling earlier intervention and treatment for patients, reducing costs compared to later stage treatments, and potentially saving lives," stated John Howell, who brings his extensive experience serving as a senior executive of public corporations to the company.
"We are very pleased to launch Arrayit Diagnostics. It is an endeavor we have been striving to achieve for some time. Arrayit Diagnostics will utilize the strong foundation built by Arrayit Corporation, and we have the utmost confidence in Mr. Howell to see that Arrayit Diagnostics succeeds," stated Rene Schena, CEO of Arrayit Corp.
Utilizing a talented sales team and its massive network of 41 international life science and diagnostics distributors located in 38 countries, Arrayit will use this opportunity to expand its worldwide customer base of 10,000 research labs to become a significant global diagnostics company.
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts